Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT02100514 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02100514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02100514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
October 28, 2014
Completion date
July 10, 2017
Enrollment
746 (actual)
Sites
223

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia